期刊文献+

尿Survivin和NMP22检测在膀胱癌早期诊断中的价值 被引量:2

下载PDF
导出
摘要 目的评价尿生存素(Survivin)和核基质蛋白(NMP22)含量测定在膀胱癌早期诊断中的应用价值,寻找早期诊断膀胱癌的理想方法。方法选择40例早期膀胱移行细胞癌和40例非膀胱肿瘤患者,进行Survivin和NMP22检测,并行尿脱落细胞学检查。结果尿Survivin、NMP22和尿脱落细胞学的敏感性分别为62.5%,65%,22.5%;特异性分别为92.5%,90%和100%;Youden指数分别为55%,55%和22.5%。尿Survivin的敏感性,特异性和Youden指数与NMP22比较差异无统计学意义(P>0.05);尿Survivin和NMP22的敏感性和Youden指数均高于尿脱落细胞学,差异有统计学意义(P<0.05)。结论尿Survivin和NMP22是早期诊断膀胱移行细胞癌的一种高敏感性和高特异性的指标。
出处 《河北医药》 CAS 2011年第3期365-366,共2页 Hebei Medical Journal
  • 相关文献

参考文献9

  • 1Martin B, Tatjana B, Ahmad S, et al. Crurrent concepts in bio-marker technology for bladder cancers. Clin Chemi ,2000,46:595.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin, 2007,57:43- 66.
  • 3Li F, Ling X. Survivin study:an update of" what is the nextwave". J Cell Physiol,2006,208:476-486.
  • 4Karam JA, Lotan Y, Ashfaq R, et al. Survivin expression in patients with non2muscle invasive urothelial cell carcinoma of the bladder. Urology, 2007,70:482-486.
  • 5Schuttz IJ, Kiemeney LA, Karthaus HF, et al. Survivin mRNA copy number in bladder washings p redicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem,2004,50:1425-1428.
  • 6Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapop tosis molecule survivin and recurrence of bladder cancer. N Engl J Med, 1999.341:452-453.
  • 7Gennaro AC, Waher MS,Joseph VB, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol, 1996.156 : 1280.
  • 8Del Nero A, Esposito N, Curro A, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa - pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol, 1999,35:93- 97.
  • 9Kang HL. Evaluation of the NMP 22 test and comparison with voided urine cytology in the detection of bladder cancer. Yonsei Med J,2001, 42:14-18.

同被引文献11

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部